Panelists discuss the utilization of second-generation BCR-ABL-targeted TKIs for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
For more from this discussion, visit [ Ссылка ]
![](https://i.ytimg.com/vi/uCKi6w-gGYQ/maxresdefault.jpg)
Panelists discuss the utilization of second-generation BCR-ABL-targeted TKIs for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
For more from this discussion, visit [ Ссылка ]